HØRSHOLM, Denmark – June 28, 2019
- On September 7, 2017, Boehringer Ingelheim and Gubra announced a collaboration for the development of novel peptide compounds to treat obesity
- In June 2019, the first clinical candidate from this collaboration was nominated, which marks the achievement of another milestone in this collaboration
- Gubra may receive up to € 250 million in combined upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales from this first obesity collaboration
- On May 29, 2019, Boehringer Ingelheim and Gubra announced a second obesity collaboration for the development of novel peptide poly-agonist.
Boehringer Ingelheim and Gubra announce the nomination of a clinical candidate for the development of novel peptide compounds to treat obesity. This marks the successful achievement of another milestone in this collaboration. The further development of the clinical candidate will be conducted by Boehringer Ingelheim.
In less than two years this collaboration has identified promising novel peptides, which are able to regulate food intake, energy homeostasis and body weight in pre-clinical models. The selected candidate has an attractive pharmaceutical profile enabling the advancement into clinical development. This joint research program complements other Boehringer Ingelheim obesity programs creating combination opportunities for the development of novel obesity treatments.
“The very rapid delivery of a co-invented clinical candidate demonstrates how combining the best aspects from biotech and pharma can speed up a research and development program”, Keld Fosgerau, CSO of Gubra says. “It is reassuring to know that the further development towards the patients is now in the hands of an experienced partner such as Boehringer Ingelheim”.
Controlling the obesity epidemic is a growing concern globally, and there are currently inadequate treatment options for the more than 650 million obesity patients worldwide. Gubra has a pipeline of early stage research and drug discovery programs addressing various metabolic conditions. The collaborations with Boehringer Ingelheim in obesity focus on targets regulating food intake and body weight control.
Henrik Blou, CEO
Phone: +45 2861 6845
Founded in 2008, Gubra is a privately-held biotech company located in Denmark delivering scientific counselling, contract research services, and projects for co-development in four main focus areas: Obesity, diabetes, NASH and diabetic complications. Gubra experts covers a number of pre-clinical disciplines: in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers by combining cutting-edge technology with our accumulated experience and proven methodology. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of research and expertise. For more information, please visit our website at www.gubra.dk.